

November 21, 2017

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719 /
22722037 / 22722039

National Stock Exchange of India Ltd.
“Exchange Plaza”
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: 500124

Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Intimation

Further to our intimation dated March 8, 2017 with regard to the US FDA audit of our Formulations Manufacturing Facility, at Duvvada, Vishakhapatnam, Andhra Pradesh, we would like to inform you that we have received the establishment inspection report (EIR) from the US FDA for the above mentioned facility, yesterday. In the cover letter to the EIR, FDA has explained that the inspection has not closed, and the site's status remains unchanged, but that FDA has released the EIR in order to be transparent about its regulatory process. We are planning to request a re-inspection in 2018 after further discussion on scheduling with FDA

This is for your information.

With regards,


Sandeep Poddar
Company Secretary

CC:- New York Stock Exchange Inc.(Stock Code :RDY)